Vanda Pharmaceuticals said on May 1, 2026, that NEREUS™ is now commercially available across the United States, giving adults a new prescription option to prevent vomiting caused by motion. The drug, tradipitant, can be ordered directly through nereus.us or filled at retail pharmacies nationwide.
The company said patients with a valid prescription can buy NEREUS™ for $85 per dose through its direct-to-consumer platform, compared with a standard list price of $255 per dose. Mihael H. Polymeropoulos, Vanda’s chief executive, said the launch marks an important milestone for the tens of millions of Americans who experience motion sickness during common travel and called the drug a selective, high-affinity antagonist of human substance P/neurokinin-1 receptors that can block the vomiting center of the brain.
Vanda said the medicine is approved to prevent vomiting induced by motion in adults and is the first new prescription drug for that condition in more than 40 years. The U.S. Food and Drug Administration approved NEREUS™ on Dec. 30, 2025, after two pivotal Phase 3 trials, Motion Syros and Motion Serifos, were conducted under real-world conditions on the open sea. Both studies showed that NEREUS™ significantly prevented vomiting compared with placebo.
Motion sickness affects an estimated 65 million to 78 million Americans, or roughly 25% to 30% of adults, according to the company. Vanda said the condition has long affected travel by car, plane and boat, and it has also posed problems for military operations, exploration and space travel. The company said nearly 70% of astronauts have faced space adaptation syndrome, underscoring how far the market has stretched beyond ordinary travel.
The launch also leaves a simple question answered: after decades without a meaningful new treatment, Vanda is now trying to make NEREUS™ available not just through pharmacies, but directly to patients who can get a prescription and pay cash. That move puts the company’s bet on convenience and access at the center of its pitch as motion sickness sufferers look for an option that did not exist in this form before.